- Home
- CERO vs VINC Comparison
CERO vs VINC Comparison
Compare CERO & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- VINC
- Stock Information
- Founded
- CERO 2017
- VINC 2019
- Country
- CERO United States
- VINC United States
- Employees
- CERO N/A
- VINC N/A
- Industry
- CERO
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- VINC Health Care
- Exchange
- CERO Nasdaq
- VINC Nasdaq
- Market Cap
- CERO 12.2M
- VINC 10.7M
- IPO Year
- CERO N/A
- VINC N/A
- Fundamental
- Price
- CERO $0.29
- VINC $0.30
- Analyst Decision
- CERO
- VINC Buy
- Analyst Count
- CERO 0
- VINC 2
- Target Price
- CERO N/A
- VINC $2.00
- AVG Volume (30 Days)
- CERO 174.9M
- VINC 365.3K
- Earning Date
- CERO 11-25-2024
- VINC 11-12-2024
- Dividend Yield
- CERO N/A
- VINC N/A
- EPS Growth
- CERO N/A
- VINC N/A
- EPS
- CERO N/A
- VINC N/A
- Revenue
- CERO N/A
- VINC N/A
- Revenue This Year
- CERO N/A
- VINC N/A
- Revenue Next Year
- CERO N/A
- VINC N/A
- P/E Ratio
- CERO N/A
- VINC N/A
- Revenue Growth
- CERO N/A
- VINC N/A
- 52 Week Low
- CERO $0.06
- VINC $0.29
- 52 Week High
- CERO $12.80
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- CERO 73.26
- VINC 28.04
- Support Level
- CERO $0.17
- VINC $0.32
- Resistance Level
- CERO $0.33
- VINC $0.38
- Average True Range (ATR)
- CERO 0.04
- VINC 0.03
- MACD
- CERO 0.02
- VINC 0.01
- Stochastic Oscillator
- CERO 57.68
- VINC 5.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.